NFE2L2 and Cholestatic liver disease: Our findings in this study suggest that when using these Nrf2 activators as hepatoprotective agents in the context of cholestatic liver disease, special attention should be paid to liver toxicity, because on the contrary, Nrf2 activation may lead to more severe liver damage.